Profile
Christopher Friedel served as Managing Director at Jazz Pharmaceuticals Germany GmbH.
He also served as a Member-Supervisory Board at APONTIS PHARMA AG from 2021 to 2022.
Dr. Friedel holds a doctorate degree from the University of Gottingen.
Former positions of Christopher Friedel
| Companies | Position | End |
|---|---|---|
| APONTIS PHARMA AG | Director/Board Member | 2022-05-11 |
Jazz Pharmaceuticals Germany GmbH
 Jazz Pharmaceuticals Germany GmbH Pharmaceuticals: MajorHealth Technology Part of Jazz Pharmaceuticals Plc, Jazz Pharmaceuticals Germany GmbH is a company committed to advancing clinical knowledge through various types of research, including non-interventional studies. The private company is based in Munich, Germany. The company adheres to established regulations, industry best practices, and internal policies to ensure the integrity of their sponsored research. Jazz Pharmaceuticals Germany is focused on improving patients' lives by developing and commercializing products that address unmet medical needs. The CEO of the company is Iain Robert McGill. | Chief Executive Officer | - |
Training of Christopher Friedel
| University of Gottingen | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| APONTIS PHARMA AG | Health Technology |
| Private companies | 1 |
|---|---|
Jazz Pharmaceuticals Germany GmbH
Jazz Pharmaceuticals Germany GmbH Pharmaceuticals: MajorHealth Technology Part of Jazz Pharmaceuticals Plc, Jazz Pharmaceuticals Germany GmbH is a company committed to advancing clinical knowledge through various types of research, including non-interventional studies. The private company is based in Munich, Germany. The company adheres to established regulations, industry best practices, and internal policies to ensure the integrity of their sponsored research. Jazz Pharmaceuticals Germany is focused on improving patients' lives by developing and commercializing products that address unmet medical needs. The CEO of the company is Iain Robert McGill. | Health Technology |
- Stock Market
- Insiders
- Christopher Friedel
